Author details

Full Name

Hartwig Huland

Affiliation

Martini-Klinik Prostate Cancer Center, University Hospital-Hamburg-Eppendorf

ORCID

Career Start Year

1971

Papers

679

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37507248	Multi-institutional Development and External Validation of a Machine Learning Model for the Prediction of Distant Metastasis in Patients Treated by Salvage Radiotherapy for Biochemical Failure After Radical Prostatectomy.	Eur Urol Focus	2024
36868922	Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate Cancer.	Eur Urol Oncol	2023
36857638	Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death.	J Clin Oncol	2023
36656332	Histopathological results of radical prostatectomy specimen of men younger than 50Â years of age at the time of surgery: possible implications for prostate cancer screening programs?	World J Urol	2023
33414516	CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo.	Cancer Gene Ther	2022
35344221	Impact of positive surgical margin length and Gleason grade at the margin on oncologic outcomes in patients with nonorgan-confined prostate cancer.	Prostate	2022
35290082	Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death.	J Clin Oncol	2022
34973856	Oncologic outcomes of organ-confined Gleason grade group 4-5 prostate cancer after radical prostatectomy.	Urol Oncol	2022
30905598	Implementation of Intraoperative Frozen Section During Radical Prostatectomy: Short-term Results from a German Tertiary-care Center.	Eur Urol Focus	2021
33628598	Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer.	Cancer Biol Med	2021
33491944	Overexpression of the TRIM24 E3 Ubiquitin Ligase is Linked to Genetic Instability and Predicts Unfavorable Prognosis in Prostate Cancer.	Appl Immunohistochem Mol Morphol	2021
33533127	Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets.	Mol Oncol	2021
33606155	Effect of prostatic apex shape (Lee types) and urethral sphincter length in preoperative MRI on very early continence rates after radical prostatectomy.	Int Urol Nephrol	2021
34902034	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.	JAMA Netw Open	2021
34101879	Long-term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life-table data.	Prostate	2021
34101827	Prostate-specific antigen levels of â¿¤4 and >4 ng/mL and risk of prostate cancer-specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer.	Cancer	2021
34092484	Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center.	Urol Oncol	2021
34196715	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features.	JAMA Netw Open	2021
34086480	Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death.	J Clin Oncol	2021
33045100	Chromosome 5 harbors two independent deletion hotspots at 5q13 and 5q21 that characterize biologically different subsets of aggressive prostate cancer.	Int J Cancer	2021
33439289	[Quality criteria in urology : How to obtain comparable results?]	Urologe A	2021
32814844	Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer.	Prostate Cancer Prostatic Dis	2021
31178293	Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trial.	Eur Urol Focus	2021
30594487	Impact of Age on Perioperative Outcomes at Radical Prostatectomy: A Population-Based Study.	Eur Urol Focus	2020
32033909	The Significance of Primary Biopsy Gleason 5 in Patients with Grade Group 5 Prostate Cancer.	Eur Urol Focus	2020
32001198	The impact of very high initial PSA on oncological outcomes after radical prostatectomy for clinically localized prostate cancer.	Urol Oncol	2020
31928867	Definition of high-risk prostate cancer impacts oncological outcomes after radical prostatectomy.	Urol Oncol	2020
31745645	Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer.	World J Urol	2020
31893572	Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients.	Cancer Med	2020
31687881	High RSF1 protein expression is an independent prognostic feature in prostate cancer.	Acta Oncol	2020
31736271	Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer.	Mol Oncol	2020
31793866	Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy.	Can Urol Assoc J	2020
32094363	Subcellular Compartmentalization of Survivin is Associated with Biological Aggressiveness and Prognosis in Prostate Cancer.	Sci Rep	2020
31648965	Impact of Adherence to Multidisciplinary Recommendations for Adjuvant Treatment in Radical Prostatectomy Patients With High Risk of Recurrence.	Clin Genitourin Cancer	2020
33339518	Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer.	BMC Cancer	2020
33195694	Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence.	Biomed Res Int	2020
32628300	Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer.	Prostate	2020
32677026	Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions.	Pathol Oncol Res	2020
32878283	Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair.	Cancers (Basel)	2020
32750503	Xenograft-derived mRNA/miR and protein interaction networks of systemic dissemination in human prostate cancer.	Eur J Cancer	2020
32417965	Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers.	Virchows Arch	2020
32245678	Validation of the updated eighth edition of AJCC for prostate cancer: Removal of pT2 substages - Does extent of tumor involvement matter?	Urol Oncol	2020
32150281	Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers.	Int J Cancer	2020
32239219	Association of Age With Risk of Adverse Pathological Findings at Radical Prostatectomy in Men With Gleason Score 6 Prostate Cancer.	JAMA Netw Open	2020
32143573	Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion.	Mol Med	2020
32467601	A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy.	Br J Cancer	2020
32377272	Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer.	Dis Markers	2020
32488048	Up regulation of the Hippo signalling effector YAP1 is linked to early biochemical recurrence in prostate cancers.	Sci Rep	2020
32424990	Martini-Klinik experience of prostate cancer surgery during the early phase of the COVID-19 pandemic.	BJU Int	2020
32317175	High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer.	Pathology	2020

1 - 50 of 679

Amirali Salmasi

University of California San Diego

Career Start Year 2005

Number of shared co-authors 6

Jun Hyuk Hong

Asan Medical Center, University of Ulsan College of Medicine

Career Start Year 2002

Number of shared co-authors 1

Tim Dudderidge

University Hospital Southampton NHS Foundation Trust

Career Start Year 2002

Number of shared co-authors 5

Michael Stoeckle

Saarland University

Career Start Year 2000

Number of shared co-authors 2

Alan Thompson

The Royal Marsden NHS Foundation Trust

Career Start Year 1996

Number of shared co-authors 3

J??rn Kamradt

Clinic of Urology and Pediatric Urology, University of Saarland

Career Start Year 1996

Number of shared co-authors 0

Omer Acar

University of Illinois at Chicago

Career Start Year 1996

Number of shared co-authors 0

Feliksas Jankevicius

Clinic of Gastroenterology, Vilnius University

Career Start Year 1995

Number of shared co-authors 2

Ganesh V Raj

University of Texas Southwestern Medical Center at Dallas

Career Start Year 1994

Number of shared co-authors 16

Louis Lacombe

CHU de Quebec-Universite Laval

Career Start Year 1994

Number of shared co-authors 12

Douglas S Scherr

New York-Presbyterian Hospital

Career Start Year 1994

Number of shared co-authors 14

Choung-Soo Kim

Asan Medical Center, University of Ulsan College of Medicine

Career Start Year 1993

Number of shared co-authors 3

Alexandre R Zlotta

University Health Network, Princess Margaret Cancer Center, University of Toronto

Career Start Year 1993

Number of shared co-authors 11

David Nicol

The Royal Marsden Hospital

Career Start Year 1993

Number of shared co-authors 5

Raymond S Lance

Washington State University Elson S. Floyd College of Medicine

Career Start Year 1992

Number of shared co-authors 6

Bernd Wullich

University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU)

Career Start Year 1989

Number of shared co-authors 4

Nicolas Mottet

Hospitalier Universitaire de Saint-Etienne

Career Start Year 1989

Number of shared co-authors 22

Damien Bolton

University of Melbourne

Career Start Year 1988

Number of shared co-authors 6

Philip Cornford

Liverpool University Hospitals

Career Start Year 1988

Number of shared co-authors 7

Christopher P Evans

University of California Davis

Career Start Year 1988

Number of shared co-authors 25

Freddie C Hamdy

University of Oxford

Career Start Year 1987

Number of shared co-authors 22

Theo M de Reijke

Amsterdam University Medical Centers, University of Amsterdam

Career Start Year 1987

Number of shared co-authors 30

Franz Recker

PolyClinic St. Moritz/Scuol

Career Start Year 1986

Number of shared co-authors 6

Joseph L Chin

University of Western Ontario

Career Start Year 1982

Number of shared co-authors 10

David E Neal

University of Oxford, John Radcliffe Hospital

Career Start Year 1981

Number of shared co-authors 11

Eric J Bergstralh

Mayo Clinic

Career Start Year 1980

Number of shared co-authors 12

Cathy Corbishley

The Institute of Cancer Research

Career Start Year 1977

Number of shared co-authors 3

Keong Tatt Foo

Rutgers Cancer Institute of New Jersey

Career Start Year 1975

Number of shared co-authors 0

Anthony J Costello

Royal Melbourne Hospital

Career Start Year 1974

Number of shared co-authors 13

Ian M Thompson

CHRISTUS Santa Rosa Hospital-Medical Center

Career Start Year 1956

Number of shared co-authors 18

row(s) 1 - 30 of 30

Markus Graefen

University Hospital Frankfurt, Goethe University Frankfurt am Main

Co-authored papers 361

Thorsten Schlomm

Charite - University Hospital Berlin

Co-authored papers 166

Guido Sauter